NCT00001805View on ClinicalTrials.gov

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 31, 1999

Study Completion Date

June 30, 2000

Conditions

Breast NeoplasmsColonic NeoplasmsLung NeoplasmsPancreatic NeoplasmsStomach Neoplasms

Interventions

DRUG

Rituximab

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH